Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multidrug resistant infections

- PMLiVE

AstraZeneca sales hit by Seroquel generics

End of patent exclusivity for antipsychotic among key factors dragging down revenues

- PMLiVE

AstraZeneca supports NHS medication passport app

Backs NIHR-NHS initiative under joint working agreement

- PMLiVE

AstraZeneca signs $200m deal with Bind for cancer drug

Follows deals with Amgen and Pfizer for Bind involving its Accurin nanotechnology

- PMLiVE

AstraZeneca signs cancer biomarkers discovery deal

Partners with UK firm on personalised oncology drug research

- PMLiVE

AZ boosts cardiovascular pipeline with US biotech acquisition

Its MedImmune biologics arm buys AlphaCore Pharma

- PMLiVE

AstraZeneca hit by US Pulmicort patent ruling

Federal court says patent for inhaled steroid drug is invalid

- PMLiVE

AstraZeneca settles with generic rivals in Crestor patent challenge

Blocks competition in US until May 2016

- PMLiVE

Additional 2,300 jobs to go at AstraZeneca

Soriot sets out strategy to return to growth

- PMLiVE

AstraZeneca cuts 1,600 jobs in overhaul of global operations

US and UK affected as Soriot pushes ahead with R&D restructuring

- PMLiVE

AZ loses Crestor patent battle in Australia

Follows challenge from Apotex

- PMLiVE

Novartis provides multimedia support to Rare Diseases Day

Collaborates with Eurordis on multimedia education campaign

- PMLiVE

AZ in atherosclerosis education drive during US Heart Month

Encouraging the public to learn more about the causes of heart disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links